Cancer biotech BeyondSpring hit by weak IPOHoping for $100m, biotech raises under $3.5 million on stock market Share XCancer biotech BeyondSpring hit by weak IPOhttps://pharmaphorum.com/news/cancer-drug-firm-beyondspring-downsizes-ipo/
BeyondSpring plans three-pronged attack on cancerThe CEO of BeyondSpring said the company hopes to make its name with a new lung cancer drug Share XBeyondSpring plans three-pronged attack on cancerhttps://pharmaphorum.com/news/chinas-beyondspring-plans-three-pronged-attack-cancer/